- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 23, 2024David Martinez Recognized Among Top 100 Lawyers in Los Angeles by LA Business Journal
-
April 15, 2024Robins Kaplan Named to 2024 BTI Client Service A-Team
-
April 9, 2024Robins Kaplan LLP Files Complaint Against Social Media Giants Meta, Snap, TikTok on Behalf of Spirit Lake Nation, Menominee Indian Tribe of Wisconsin
-
April 30, 2024Navigating Generational Dynamics
-
May 2-3, 2024ACI Advanced Forum on Managed Care Disputes and Litigation
-
May 6, 2024Litigating with the Legends
-
March 2024e-Commerce: Pitfalls and Protections
-
March 22, 2024‘In re Cellect’:
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
GENERICally Speaking Hatch Waxman Bulletin
The Hatch-Waxman Litigation practice group at Robins Kaplan LLP is pleased to offer the latest edition of their quarterly publication regarding ANDA patent litigation issues and the generics business.
Vol. 9, No. 1
Spring 2019
Relevant court decisions highlighted in this issue:
- Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc.
A commercial sale to a third party who is required to keep the invention confidential may place the invention “on sale” under § 102(a). - Endo Pharms. Inc. v. Teva Pharms. USA, Inc.
The Federal Circuit reversed the district court’s holding that the claims of the ’737 patent were ineligible under 35 U.S.C. § 101. - Grünenthal GmbH v. Alkem Labs. Ltd.
Finding no clear error on the part of the district court concerning the issues of non-obviousness and non-infringement resulting from a “section viii” carve-out, the Federal Circuit affirmed.
Relevant ANDA updates highlighted in this issue:
- ANDA Approvals
- ANDA Litigation Settlements
- Generic Launches
- New ANDA Cases
Related Professionals
Christopher A. Pinahs
Partner
A Hatch-Waxman Act complaint complies with the requirements of Iqbal and Twombly when it alleges plaintiff’s: (i) interest in the patent, (ii) receipt of the paragraph IV certification, (iii) knowledge of the filing of the ANDA or NDA, and (iv) contention that the defendant’s proposed product will infringe.
The Federal Circuit reversed the district court’s holding that the claims of the ’737 patent were ineligible under 35 U.S.C. § 101.
Finding no clear error on the part of the district court concerning the issues of non-obviousness and non-infringement resulting from a “section viii” carve-out, the Federal Circuit affirmed.
Judgment of non-infringement vacated as a result of improper claim construction and judgment of non-obviousness remanded to make an express finding on motivation to combine references.
JMOL of non-infringement was affirmed when the data relied on for proving infringement were speculative and not within the parameters of the district court’s claim construction.
Because plaintiff did not have standing, its motion for a preliminary injunction to bar the FDA from depriving it of its 180-day marketing exclusivity was denied and defendants’ motion to dismiss was granted.
Dismissal granted when plaintiff made no allegation (or reasonable basis to infer) that defendant would be involved in the commercial manufacture, use, or sale of ANDA applicant’s product after FDA approval.
Disqualification was permitted when law firm’s representation of defendant gave rise to a concurrent conflict of interest under Model Rule 1.7.
A commercial sale to a third party who is required to keep the invention confidential may place the invention “on sale” under § 102(a).
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.